Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting
for> 6 weeks with onset before 16 years of age. JIA is the most common chronic …

Juvenile idiopathic arthritis (JIA), as a chronic condition, is associated with significant
disease-and treatment-related morbidity, thus impacting children's quality of life. In order to …

Objective To provide updated guidelines for pharmacologic management of juvenile
idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint …

Background Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and
safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic …

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …

Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic
arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human …

Background Juvenile idiopathic arthritis can be refractory to some or all treatment regimens,
therefore new medications are needed to treat this population. This trial assessed the …

Objective The present study was undertaken to assess the long‐term course, remission rate,
and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a …

Objective To investigate the characteristics and risk factors of a novel parenchymal lung
disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). Methods In …

Objective To describe clinical outcomes of juvenile idiopathic arthritis (JIA) in a prospective
inception cohort of children managed with contemporary treatments. Methods Children …